Olema Oncology

Contributing Author

Recent Articles by Olema Oncology

Apr-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Mar-17	Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting OLMA -9.31% GlobeNewswire
Mar-16	Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results OLMA +12.85% GlobeNewswire
Mar-03	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Feb-19	Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference OLMA +6.25% GlobeNewswire
Feb-04	Olema Oncology to Participate in Upcoming Investor Conferences OLMA -5.05% OLMA GlobeNewswire
Feb-03	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Jan-30	Olema Oncology Announces Departure of Chief Operating and Financial Officer OLMA GlobeNewswire
Jan-05	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Jan-05	Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference OLMA GlobeNewswire
Dec-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Nov-21	Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference OLMA +8.11% OLMA +5.27% GlobeNewswire
Nov-20	Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares OLMA +13.28% GlobeNewswire
Nov-19	Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock OLMA GlobeNewswire
Nov-18	Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants OLMA +136.38% GlobeNewswire
Nov-10	Olema Oncology Reports Third Quarter 2025 Financial and Operating Results OLMA GlobeNewswire
Nov-04	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Nov-03	Olema Oncology to Participate in Upcoming Investor Conferences OLMA -6.13% GlobeNewswire
Oct-30	Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 OLMA GlobeNewswire
Oct-18	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 OLMA GlobeNewswire
Oct-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Sep-03	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Sep-02	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer OLMA +18.50% GlobeNewswire
Aug-20	Olema Oncology to Participate in Upcoming Investor Conferences OLMA GlobeNewswire
Aug-11	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results OLMA +16.19% OLMA GlobeNewswire
Aug-04	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Jul-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Jun-03	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA -7.43% GlobeNewswire
May-28	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting OLMA GlobeNewswire
May-21	Olema Oncology to Participate in Upcoming Investor Conferences OLMA GlobeNewswire
May-13	Olema Oncology Reports First Quarter 2025 Financial and Operating Results OLMA GlobeNewswire
May-09	Olema Oncology to Participate in Upcoming Investor Conferences OLMA GlobeNewswire
May-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA +6.24% GlobeNewswire

Olema Oncology

Recent Articles by Olema Oncology

Upgrade your Finviz experience